Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK579033PMID: 35349237
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 308242-62-8
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the use of remimazolam during breastfeeding. Because it is very short acting, it is recommended that nursing mothers pump and discard breast milk for 5 hours after a dose. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Intravenous Sedation) Dexmedetomidine, Etomidate, Methohexital, Midazolam, Propofol
Substance Identification
Substance Name
Remimazolam
CAS Registry Number
308242-62-8
Drug Class
Breast Feeding
Lactation
Hypnotics and Sedatives
Benzodiazepines
Anesthetics, Intravenous
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.